Ticker: ACRS

Aclaris Therapeutics (NASDAQ: ACRS) begins a Phase 1 trial for its bispecific antibody ATI-052, targeting inflammation. H.C. Wainwright maintains a "Buy" rating with a $16 price target. Key results expected in 2026 may impact stock volatility and investment strategies.